Page 2

Virogin generates $80m in financing
The Sinopharm-backed oncology drug developer has raised series D1 funding in a round led by China Structural Reform Fund Corporation.
Jasper Therapeutics jumps at reverse merger opportunity
Roche Venture Fund and Amgen will invest in the stem cell-transplant technology developer through a reverse merger transaction which will give it a $490m market capitalisation.
Science 37 experiments with reverse takeover
The Sanofi, Amgen, Alphabet, Novartis and PPD-backed clinical trials software producer is joining forces with publicly listed LifeSci Acquisition II Corp.
Gyroscope Therapeutics gives up $149m IPO
The Fosun-backed gene therapy developer had set terms for an offering set to raise between $135m and $149m on the Nasdaq Global Select Market.
Corporates illuminate Lightmatter in $80m series B
Alphabet, Hewlett Packard Enterprise and Lockheed Martin invested in the photonic computing technology developer’s series B round, increasing its total funding to $113m. decides on $2.5bn Divvy acquisition
Hanaco and PayPal are set to exit Divvy, a provider of corporate spend management software, at a 56% premium to the valuation at which they invested in January.
Day One initiates IPO process
The Takeda and Access Industries-backed oncology therapeutics developer is targeting an offering on the Nasdaq Global Market having previously raised $190m.
Dyno Therapeutics evolves to raise $100m
GV was among the investors in a series A round led by Andreessen Horowitz closed three years after the gene therapy developer's launch.
Vast Data vaults to $83m series D
Nvidia participated in a round valuing the data storage technology provider, which counts Dell, Siemens and Mellanox as investors, at $3.7bn.

test reg